Management of squamous cell carcinoma of the head and neck: Updated European treatment recommendations

Monica Ramos, Sergi Benavente, Jordi Giralt*

*Autor corresponent d’aquest treball

Producció científica: Contribució a revistaArticle de revisióRecercaAvaluat per experts

24 Cites (Scopus)

Resum

Squamous cell carcinoma of the head and neck requires a multidisciplinary management. Risk factors for adjuvant radiotherapy are stage III-IV, perineural involvement or vascular tumor embolism. If there are positive margins or extracapsular extension chemoradiotherapy is needed. For patients with nonresectable disease we recommend treatment with concomitant chemoradiation, although this has important acute and late toxicity. Concomitant EGF receptor inhibitors and taxane-based induction chemotherapy are new strategies under study that have demonstrated some benefits but are not yet the standard treatment. Intensity-modulated radiotherapy allows one to decrease radiation dose to organs. Preclinical work in signaling pathways and other oncogenic factors (e.g., human papillomavirus infection) will be the key to improving outcomes of head and neck cancer patients in the future.
Idioma originalAnglès
Pàgines (de-a)339-344
Nombre de pàgines6
RevistaExpert Review of Anticancer Therapy
Volum10
Número3
DOIs
Estat de la publicacióPublicada - de març 2010

Fingerprint

Navegar pels temes de recerca de 'Management of squamous cell carcinoma of the head and neck: Updated European treatment recommendations'. Junts formen un fingerprint únic.

Com citar-ho